IRCCS Istituto Tumori "Giovanni Paolo II" of Bari, Italy; Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", Bari, Italy.
IRCCS Istituto Tumori "Giovanni Paolo II" of Bari, Italy.
Crit Rev Oncol Hematol. 2020 Oct;154:103066. doi: 10.1016/j.critrevonc.2020.103066. Epub 2020 Aug 15.
The growing insights in the next-generation immunotherapy and the state-of-the-art advancement in targeted-agents significantly improved clinical outcome of cancer patients by pointing towards a unexplored Achilles' heel. Novel toxicity profiles have been uncovered, representing unmet medical needs. Thus, a panel of expert provide comprehensive pharmacological and clinical evidence, to provide a patient-tailored approach to metabolic adverse events associated with novel anti-cancer treatments. Prompted by the need of a multidisciplinary cooperation, a working group of Associazione Italiana Oncologia Medica (AIOM), Associazione Medici Diabetologi (AMD) and Società Italiana Farmacologia (SIF) examined the available literature data. The identification of patient risk profile and the characterization of metabolic effects of novel anti-tumour drugs is clearly a clinical challenge that can be addressed by a multidisciplinary clinical approach. Therefore, this review pinpoints the relevance of the challenging profiling of the patient suffering from dysmetabolic conditions induced by the novel therapeutics in medical oncology.
下一代免疫疗法的不断深入研究和靶向药物的最新进展，通过指向一个未被探索的阿喀琉斯之踵，显著改善了癌症患者的临床预后。新型毒性特征已经被发现，代表了未满足的医疗需求。因此，一组专家提供了全面的药理学和临床证据，为与新型抗癌治疗相关的代谢不良事件提供了个体化的治疗方法。由于需要多学科合作，意大利肿瘤医学协会（AIOM）、意大利糖尿病医生协会（AMD）和意大利药理学学会（SIF）的一个工作组审查了现有文献数据。确定患者的风险特征和新型抗肿瘤药物的代谢作用特征显然是一个临床挑战，可以通过多学科的临床方法来解决。因此，本综述指出了对患有代谢紊乱的患者进行新型治疗药物相关挑战性分析的重要性。
